Zhang Qiyao, Yu Xiao, Zheng Qingyuan, He Yuting, Guo Wenzhi
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2020 Sep 23;10:560229. doi: 10.3389/fonc.2020.560229. eCollection 2020.
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world with a very poor prognosis. Immunotyping is of great significance for predicting HCC outcomes and guiding immunotherapy. Therefore, we sought to establish a reliable prognostic model for HBV-related HCC based on immune scores. We identified immune-related modules of The Cancer Genome Atlas LIHC and GSE14520 data sets through weighted gene co-expression network analysis and evaluated HCC through a non-negative matrix factorization algorithm. Through further bioinformatics analyses, we identified causes for prognostic differences between subtypes. The results illustrate a significant difference in prognosis based on immunotypes, which may stem from metabolic disorders and increased tumor invasion associated with the high expression of genes related to stem cell characteristics. In conclusion, we identified a novel HBV-related HCC immune subtype and determined its immunological characteristics, which provides ideas for further individualized immunotherapy research.
乙型肝炎病毒(HBV)相关肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一,预后很差。免疫分型对于预测HCC预后和指导免疫治疗具有重要意义。因此,我们试图基于免疫评分建立一个可靠的HBV相关HCC预后模型。我们通过加权基因共表达网络分析确定了癌症基因组图谱LIHC和GSE14520数据集的免疫相关模块,并通过非负矩阵分解算法评估HCC。通过进一步的生物信息学分析,我们确定了亚型之间预后差异的原因。结果表明,基于免疫型的预后存在显著差异,这可能源于代谢紊乱以及与干细胞特征相关基因高表达导致的肿瘤侵袭增加。总之,我们确定了一种新的HBV相关HCC免疫亚型并确定了其免疫学特征,为进一步的个体化免疫治疗研究提供了思路。